Jakarta - PT Indofarma Tbk (INAF) until January-September 2021 posted a profit attributable to owners of the parent entity of Rp2.82 billion, an increase compared to the same period the previous year, which suffered a loss of Rp18.88 billion.

The financial report released Monday (1/11), this profit achievement was supported by a nearly doubled increase in net sales to Rp1.49 trillion from Rp749.25 billion.

However, the cost of goods sold almost doubled or from Rp565.74 billion to Rp1.001 trillion.

Operating profit increased more than seven times to Rp48.48 billion from Rp6.93 billion.

As of the end of September 2021, the company's total assets were recorded at Rp2.33 trillion, with liabilities of Rp. 1.90 trillion and equity of Rp433.16 billion.